Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney

Journal of Nephropathology

Volumn 2, Issue 3, 2013, Pages 154-165

  Gobe, Glenda C ^a   Morais, Christudas ^a   Vesey, David A ^a,b   Johnson, David W ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Cytokine; Cytoprotection; Erythropoietin; Heart; Ischemia reperfusion; Kidney

Indexed keywords

EID: 84877948678     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.12860/JNP.2013.27     Document Type: Review

References (81)

1. Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35(4):349-55.
2. Halim SA, Newby LK. Prognostic biomarkers in individuals with prevalent coronary heart disease. Dis Markers. 2009;26(5-6):265-71.
3. World Health Organization. Cardiovascular Diseases. 2012 [cited 2012 20 Novemebr 2012]; Available from:.
4. World Health Organization. Global status report on noncommunicable diseases. 2010.
5. Munugalavadla V, Kapur R. Role of c-Kit and erythropoietin receptor in erythropoiesis. Crit Rev Oncol Hematol. 2005;54(1):63-75.
6. Johnson DW, Vesey DA, G.C. G. Erythropoietin protects against acute kidney injury and failure. Open Drug Discovery Journal. 2009;1:41-50.
7. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant. 2004;19(2):348-55.
8. Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006;69(10):1806-13.
9. Weng S, Zhu X, Jin Y, Wang T, Huang H. Protective effect of erythropoietin on myocardial infarction in rats by inhibition of caspase-12 expression. Experimental and therapeutic medicine. 2011;2(5):833-6.
10. Lu MJ, Chen YS, Huang HS, Ma MC. Erythropoietin alleviates post-ischemic injury of rat hearts by attenuating nitrosative stress. Life Sci. 2012;90(19-20):776-84.
11. Li XJ, Wang XW, Du YJ. Protective effects of erythropoietin on myocardial infarction in rats: the role of AMP-activated protein kinase signaling pathway. Am J Med Sci. 2011;342(2):153-9.
12. Sharples EJ, Thiemermann C, Yaqoob MM. Novel applications of recombinant erythropoietin. Curr Opin Pharmacol. 2006;6(2):184-9.
13. Hong Z, Hong H, Chen H, Wang Z, Hong D. Investigation of the protective effect of erythropoietin on spinal cord injury in rats. Experimental and therapeutic medicine. 2011;2(5):837-41.
14. Rong X, Mo X, Ren T, Yang S, Yuan W, Dong J, et al. Neuroprotective effect of erythropoietin-loaded composite microspheres on retinal ganglion cells in rats. European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences. 2011;43(4):334-42.
15. Bader A, Ebert S, Giri S, Kremer M, Liu S, Nerlich A, et al. Skin regeneration with conical and hair follicle structure of deep second-degree scalding injuries via combined expression of the EPO receptor and beta common receptor by local subcutaneous injection of nanosized rhEPO. International journal of nanomedicine. 2012;7:1227-37.
16. Elfar JC, Jacobson JA, Puzas JE, Rosier RN, Zuscik MJ. Erythropoietin accelerates functional recovery after peripheral nerve injury. The Journal of bone and joint surgery American volume. 2008;90(8):1644-53.
17. Kao NR, Xenocostas A, Driman DK, Rui T, Huang W, Jiao X, et al. Recombinant human erythropoietin improves gut barrier function in a hemorrhagic shock and resuscitation rat model. The Journal of trauma. 2011;71(5 Suppl 1):S456-61.
18. Kakavas S, Demestiha T, Vasileiou P, Xanthos T. Erythropoetin as a novel agent with pleiotropic effects against acute lung injury. European journal of clinical pharmacology. 2011;67(1):1-9.
19. Cuzzocrea S, Mazzon E, Di Paola R, Patel NS, Genovese T, Muia C, et al. Erythropoietin reduces the development of experimental inflammatory bowel disease. J Pharmacol Exp Ther. 2004;311(3):1272-80.
20. Guneli E, Cavdar Z, Islekel H, Sarioglu S, Erbayraktar S, Kiray M, et al. Erythropoietin protects the intestine against ischemia/ reperfusion injury in rats. Molecular medicine. 2007;13(9-10):509-17.
21. Shawky HM, Younan SM, Rashed LA, Shoukry H. Effect of recombinant erythropoietin on ischemia-reperfusion-induced apoptosis in rat liver. Journal of physiology and biochemistry. 2012;68(1):19-28.
22. Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med. 2010;207(13):2831-42.
23. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol. 2009;30(3):253-60.
24. Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, et al. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int. 2010;77(11):1020-30.
25. Prunier F, Biere L, Gilard M, Boschat J, Mouquet F, Bauchart JJ, et al. Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in myocardial infarction trial. Am Heart J. 2012;163(2):200-7 e1.
26. Erythropoietin in acute myocardial infarction (EAMI) NCT00149058. 2005.
27. EPOMI Study: ErythroPOietin in Myocardial Infarction NCT00648089. 2011.
28. Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction (HEBEIII) NCT00449488. 2009.
29. MAGIC Cell-5-Combicytokine Trial NCT00501917. 2007.
30. REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction NCT00378352. 2012.
31. Bachmann S, Le HM, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-5’-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem. 1993;41(3):335-41.
32. Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest. 1988;81(2):620-3.
33. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228(1):1-14.
34. Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: new uses for an old hormone. Nephrology (Carlton). 2006;11(4):306-12.
35. Brines M, Grasso G, Fiordaliso F, Sfacteria A, Ghezzi P, Fratelli M, et al. Erythropoietin mediates tissue protection through an erythropoietin and common be ta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101(41):14907-12.
36. Wojchowski DM, He TC. Signal transduction in the erythropoietin receptor system. Stem Cells. 1993;11(5):381-92.
37. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412(6847):641-7.
38. Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol. 2004;83(11):673-86.
39. Lippi G, Franchini M, Favaloro EJ. Thrombotic complications of erythropoiesis-stimulating agents. Seminars in thrombosis and hemostasis. 2010;36(5):537-49.
40. Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science. 2004;305(5681):239-42.
41. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2005;102(6):2046-51.
42. Hadland BK, Longmore GD. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27(25):4217-26.
43. Li J, Vesey DA, Johnson DW, Gobe G. Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther. 2007;6(12):1944-50.
44. Gethin G. Understanding the inflammatory process in wound healing. Br J Community Nurs. 2012;Suppl:S17-8, S20, S2.
45. Koh TJ, DiPietro LA. Inflammation and wound healing: the role of the macrophage. Expert Rev Mol Med. 2011;13:e23.
46. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057-66.
47. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol. 2003;163(3):993-1000.
48. Coleman T, Brines M. Science review: recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care. 2004;8(5):337-41.
49. Hoffman JW, Jr., Gilbert TB, Poston RS, Silldorff EP. Myocardial reperfusion injury: etiology, mechanisms, and therapies. J Extra Corpor Technol. 2004;36(4):391-411.
50. Wang Y, Harris DC. Macrophages in renal disease. J Am Soc Nephrol. 2011;22(1):21-7.
51. Johnson DW, Saunders HJ, Brew BK, Ganesan A, Baxter RC, Poronnik P, et al. Human renal fibroblasts modulate proximal tubule cell growth and transport via the IGF-I axis. Kidney Int. 1997;52(6):1486-96.
52. Yang T, Pat BK, Veset D, Johnson DW, Wei MQ, Gobe GC. Renal tubulointerstitial fibrosis: role of apoptosis of myofibroblasts in limiting pro-fibrotic factors. Transl Res. 2007;150:40-50.
53. Gobe GC, Vesey DA, Bennett N, Johnson, DW. Recombinant human erythropoietin reduces ischemic acute kidney injury but does not stop progression to chronic kidney disease. Nephrology (Carlton). 2008;13 (3):A135 (Abstr).
54. Brodsky SV, Yamamoto T, Tada T, Kim B, Chen J, Kajiya F, et al. Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol. 2002;282(6):F1140-9.
55. Buja LM, Vela D. Cardiomyocyte death and renewal in the normal and diseased heart. Cardiovasc Pathol. 2008;17(6):349-74.
56. Larsson SH, Aperia A. Renal growth in infancy and childhood--experimental studies of regulatory mechanisms. Pediatr Nephrol. 1991;5(4):439-42.
57. Chatterjee S, Stewart AS, Bish LT, Jayasankar V, Kim EM, Pirolli T, et al. Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic postischemic heart failure. Circulation. 2002;106(12 Suppl 1):I212-7.
58. Donath S, Li P, Willenbockel C, Al-Saadi N, Gross V, Willnow T, et al. Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation. 2006;113(9):1203-12.
59. McGaffin KR, Zou B, McTiernan CF, O’Donnell CP. Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res. 2009;83(2):313-24.
60. Arenal A, Hernandez J, Perez-David E, Rubio-Guivernau JL, Ledesma-Carbayo MJ, Fernandez-Aviles F. Do the spatial characteristics of myocardial scar tissue determine the risk of ventricular arrhythmias? Cardiovasc Res. 2012;94(2):324-32.
61. Dor V, Civaia F, Alexandrescu C, Montiglio F. The post-myocardial infarction scarred ventricle and congestive heart failure: the preeminence of magnetic resonance imaging for preoperative, intraoperative, and postoperative assessment. J Thorac Cardiovasc Surg. 2008;136(6):1405-12.
62. Reinecke H, MacDonald GH, Hauschka SD, Murry CE. Electromechanical coupling between skeletal and cardiac muscle. Implications for infarct repair. J Cell Biol. 2000;149(3):731-40.
63. Yang L, Humphreys BD, Bonventre JV. Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contributions to nephrology. 2011;174:149-55.
64. Pat B, Hughson MD, Nicol JL, Hoy WE, Gobe GC. A comparison of pathomolecular markers of fibrosis and morphology in kidney from autopsies of African Americans and whites. Virchows Arch. 2007;450(1):41-50.
65. Gobe G, Zhang XJ, Willgoss DA, Schoch E, Hogg NA, Endre ZH. Relationship between expression of Bcl-2 genes and growth factors in ischemic acute renal failure in the rat. J Am Soc Nephrol. 2000;11(3):454-67.
66. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116(2):288-96.
67. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. Faseb J. 2004;18(9):1031-3.
68. Bogoyevitch MA. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res. 2004;63(2):208-16.
69. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van VDJ, van GWH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol. 2006;48(11):2161-7.
70. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol. 2007;293(1):H60-8.
71. van der Meer P, Lipsic E, Henning RH, Boddeus K, van d VJ, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol. 2005;46(1):125-33.
72. van der Meer P, Lipsic E, van GWH, van VDJ. Erythropoietin: from hematopoiesis to cardioprotection. Cardiovasc Drugs Ther. 2005;19(1):7-8.
73. Prunier F, Pfister O, Hadri L, Liang L, Del MF, Liao R, et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol. 2007;292(1):H522-9.
74. Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M, et al. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res. 2008;79(4):611-20.
75. Kobayashi H, Miura T, Ishida H, Miki T, Tanno M, Yano T, et al. Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion. Clin Exp Pharmacol Physiol. 2008;35(7):812-9.
76. Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol. 2005;45(9):1406-12.
77. Ferrario M, Massa M, Rosti V, Campanelli R, Ferlini M, Marinoni B, et al. Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J. 2007;28(15):1805-13.
78. Tilling L, Clapp B. Erythropoietin: a future therapy for failing hearts? Heart Fail Rev. 2012;17(3):475-83.
79. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77(2):176-85.
80. Forman CJ, Johnson DW, Nicol DL. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int. 2007;99(1):162-5.
81. Andratschke N, Schnaiter A, Weber WA, Cai L, Schill S, Wiedenmann N, et al. Preclinical evaluation of erythropoietin administration in a model of radiation-induced kidney dysfunction. Int J Radiat Oncol Biol Phys. 2006;64(5):1513-8.